Clovis reports $66.4M loss for Q2 2021
BOULDER — Cancer-drug manufacturer Clovis Oncology Inc. (NYSE: CLVS) posted a net loss of $66.4 million, or $0.61 per share, in its second quarter earnings that were reported Wednesday.
That loss is 33% smaller than the $92.2 million, or $1.15 per share, loss that Clovis reported in the second quarter of 2020.
Clovis also reported an 8% decrease in year-over-year revenue, from $39.9 million last year to $36.8 million this year. In a press release, the company attributed that to fewer patients starting cancer treatment during the COVID-19 pandemic.
SPONSORED CONTENT
Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply
Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).
Research and development spending was down 35%, from $69.9 million to $45.8 million, which Clovis again attributed to the pandemic inhibiting drug trials.
As of June 30, Clovis had $230.2 million in cash and cash equivalents.
Clovis stock closed Wednesday at $4.82 per share, down 0.82% from open.
